121 related articles for article (PubMed ID: 10846530)
1. [CD44 expression: a new prognostic factor in neuroblastoma].
Combaret V; Lasset C; Bouvier R; Frappaz D; Thiesse P; Rebillard AC; Philip T; Favrot MC
Bull Cancer; 1995 Jan; 82(2):131-6. PubMed ID: 10846530
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors.
Combaret V; Lasset C; Frappaz D; Bouvier R; Thiesse P; Rebillard AC; Philip T; Favrot MC
Eur J Cancer; 1995; 31A(4):545-9. PubMed ID: 7576964
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas.
Combaret V; Gross N; Lasset C; Frappaz D; Peruisseau G; Philip T; Beck D; Favrot MC
J Clin Oncol; 1996 Jan; 14(1):25-34. PubMed ID: 8558206
[TBL] [Abstract][Full Text] [Related]
4. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression.
Combaret V; Gross N; Lasset C; Balmas K; Bouvier R; Frappaz D; Beretta-Brognara C; Philip T; Favrot MC; Coll JL
Br J Cancer; 1997; 75(8):1151-5. PubMed ID: 9099963
[TBL] [Abstract][Full Text] [Related]
6. CD44 expression in neuroblastoma and related tumors.
Comito MA; Savell VH; Cohen MB
J Pediatr Hematol Oncol; 1997; 19(4):292-6. PubMed ID: 9256826
[TBL] [Abstract][Full Text] [Related]
7. [Expression of CD44-standard in 182 primary neuroblastomas].
Christiansen H; Terpe HJ; Gonzales M; Wenderhold S; Berthold F; Lampert F
Klin Padiatr; 1995; 207(4):219-21. PubMed ID: 7564156
[TBL] [Abstract][Full Text] [Related]
8. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma.
Christiansen H; Sahin K; Berthold F; Hero B; Terpe HJ; Lampert F
Eur J Cancer; 1995; 31A(4):541-4. PubMed ID: 7576963
[TBL] [Abstract][Full Text] [Related]
9. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma.
Combaret V; Gross N; Lasset C; Frappaz D; Beretta-Brognara C; Philip T; Beck D; Favrot MC
Eur J Cancer; 1997 Oct; 33(12):2101-5. PubMed ID: 9516862
[TBL] [Abstract][Full Text] [Related]
11. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
12. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.
Burgues O; Navarro S; Noguera R; Pellín A; Ruiz A; Castel V; Llombart-Bosch A
Virchows Arch; 2006 Oct; 449(4):410-20. PubMed ID: 16941154
[TBL] [Abstract][Full Text] [Related]
14. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.
Kim DK; Alvarado CS; Abramowsky CR; Gu L; Zhou M; Soe MM; Sullivan K; George B; Schemankewitz E; Findley HW
Pediatr Dev Pathol; 2005; 8(6):621-9. PubMed ID: 16328668
[TBL] [Abstract][Full Text] [Related]
15. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.
Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU
Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861
[TBL] [Abstract][Full Text] [Related]
16. Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s.
Terpe HJ; Christiansen H; Gonzalez M; Berthold F; Lampert F
Eur J Cancer; 1995; 31A(4):549-52. PubMed ID: 7576965
[TBL] [Abstract][Full Text] [Related]
17. Identification of GRP75 as an independent favorable prognostic marker of neuroblastoma by a proteomics analysis.
Hsu WM; Lee H; Juan HF; Shih YY; Wang BJ; Pan CY; Jeng YM; Chang HH; Lu MY; Lin KH; Lai HS; Chen WJ; Tsay YG; Liao YF; Hsieh FJ
Clin Cancer Res; 2008 Oct; 14(19):6237-45. PubMed ID: 18829503
[TBL] [Abstract][Full Text] [Related]
18. [N-myc gene copies in children with neuroblastoma and its clinical significance].
Ma XL; Gong LP; Zhou CJ; Zhang DW; Jin M; Wang HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1447-51. PubMed ID: 23257451
[TBL] [Abstract][Full Text] [Related]
19. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.
Nakagawara A; Arima-Nakagawara M; Scavarda NJ; Azar CG; Cantor AB; Brodeur GM
N Engl J Med; 1993 Mar; 328(12):847-54. PubMed ID: 8441429
[TBL] [Abstract][Full Text] [Related]
20. Distribution of natural antibody against human neuroblastoma among children with or without neuroblastoma.
Fukuda M; Nozaki C; Ishiguro Y; Horibe K
Med Pediatr Oncol; 2001 Jan; 36(1):147-8. PubMed ID: 11464870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
